Kuruvilla ME, et al. Clin Rev Allergy Immunol. 2019;56(2): 219-233.-233.
Corren J. J Allergy Clin Immunol Pract. 2019;7(5):1394-1403
Sullivan PW, et al. J Allergy Clin Immunol. 2018;141(1):110-116.e7.
Fitzpatrick AM, et al. J Allergy Clin Immunol Pract. 2020;8(2):452-463.
Hinks TSW, et al. Eur Respir J. 2021;57(1):2000528.
Corren J, et al. N Engl J Med. 2017;377(10):936-946.
Efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study.
Menzies-Gow A, et al. J Allergy Clin Immunol. 2021;147(2):AB249.
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial.
Kelsen SG, et al. J Allergy Clin Immunol. 2021;S0091-6749(21)00609-6.
Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.
Busse WW, et al. Am J Respir Crit Care Med. 2013;188(11):1294-1302.
Patient Advocacy Organizations and Resources
AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.
The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.
The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.
The CHEST Foundation creates trusted patient education resources and disease awareness campaigns that empower patients to engage in better managing their health.